Details for New Drug Application (NDA): 020920
✉ Email this page to a colleague
The generic ingredient in NATRECOR is nesiritide recombinant. There are two drug master file entries for this compound. Additional details are available on the nesiritide recombinant profile page.
Summary for 020920
Tradename: | NATRECOR |
Applicant: | Scios Llc |
Ingredient: | nesiritide recombinant |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SOLUTION;INTRAVENOUS | Strength | 1.5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Aug 10, 2001 | TE: | RLD: | Yes |
Expired US Patents for NDA 020920
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Scios Llc | NATRECOR | nesiritide recombinant | FOR SOLUTION;INTRAVENOUS | 020920-001 | Aug 10, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
Scios Llc | NATRECOR | nesiritide recombinant | FOR SOLUTION;INTRAVENOUS | 020920-001 | Aug 10, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
Scios Llc | NATRECOR | nesiritide recombinant | FOR SOLUTION;INTRAVENOUS | 020920-001 | Aug 10, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription